Literature DB >> 24366649

'Spinal amaurosis' (1841). On the early contribution of Edward Hocken to the concept of neuromyelitis optica.

S Jarius1, B Wildemann.   

Abstract

While the history of classical multiple sclerosis has been extensively studied, only little is known about the early history of neuromyelitis optica (Devic's syndrome). Here we discuss a forgotten report by Edward Octavius Hocken (1820-1845) published in The Lancet in 1841. Hocken's report is important from a historic point of view for two reasons. Firstly, apart from a French language report by Antoine Portal, no earlier case of spinal cord inflammation and amaurosis is known. Secondly and much more importantly, Hocken, who upon his untimely death at the age of just 25 years was honoured by his contemporaries as a "precocious talent" of "very early reputation", in that article propagated the novel concept of 'spinal amaurosis', i.e. the concept of acute amaurosis and spinal cord disease being pathogenetically connected. Hocken's ideas predate Devic and Gault's seminal works on 'neuromyelitis optica' by more than 50 years.

Entities:  

Mesh:

Year:  2013        PMID: 24366649     DOI: 10.1007/s00415-013-7210-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  31 in total

1.  Edward Octavius Hocken (1820-1845); life and writings of a forgotten man.

Authors:  R A HUNTER; J L THORNTON
Journal:  Med Hist       Date:  1958-01       Impact factor: 1.419

Review 2.  Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature.

Authors:  Sven Jarius; Brigitte Wildemann
Journal:  Brain Pathol       Date:  2013-11       Impact factor: 6.508

3.  Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus.

Authors:  Jakub Závada; P Nytrová; K P Wandinger; S Jarius; R Svobodová; C Probst; V Peterová; D Tegzová; K Pavelka; J Vencovský
Journal:  Rheumatol Int       Date:  2011-10-29       Impact factor: 2.631

4.  Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: case report and review of the literature.

Authors:  S Jarius; K P Wandinger; K Borowski; W Stoecker; B Wildemann
Journal:  Clin Neurol Neurosurg       Date:  2011-12-03       Impact factor: 1.876

5.  An early case of neuromyelitis optica: on a forgotten report by Jacob Lockhart Clarke, FRS.

Authors:  S Jarius; B Wildemann
Journal:  Mult Scler       Date:  2011-06-20       Impact factor: 6.312

6.  On the contribution of Thomas Clifford Allbutt, F.R.S., to the early history of neuromyelitis optica.

Authors:  S Jarius; B Wildemann
Journal:  J Neurol       Date:  2012-07-11       Impact factor: 4.849

7.  'Noteomielite' accompanied by acute amaurosis (1844). An early case of neuromyelitis optica.

Authors:  S Jarius; B Wildemann
Journal:  J Neurol Sci       Date:  2011-10-10       Impact factor: 3.181

8.  The history of neuromyelitis optica.

Authors:  Sven Jarius; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2013-01-15       Impact factor: 8.322

Review 9.  Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica.

Authors:  Sven Jarius; Friedemann Paul; Diego Franciotta; Patrick Waters; Frauke Zipp; Reinhard Hohlfeld; Angela Vincent; Brigitte Wildemann
Journal:  Nat Clin Pract Neurol       Date:  2008-03-11

10.  IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors:  Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal:  J Exp Med       Date:  2005-08-08       Impact factor: 14.307

View more
  2 in total

Review 1.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

Review 2.  The history of neuromyelitis optica. Part 2: 'Spinal amaurosis', or how it all began.

Authors:  S Jarius; B Wildemann
Journal:  J Neuroinflammation       Date:  2019-12-28       Impact factor: 8.322

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.